Patents Examined by Gregg Polansky
  • Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof
    Patent number: 11083699
    Abstract: Compounds and compositions including stereoisomers of 6-phenylhexanamide derivative small molecule mitofusin activators are described. In particular, mitofusin activators comprising derivatives of (trans-4-hydroxycyclohexyl)-6-phenylhexanamide, which are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin-1 (MFN1) and/or mitofusin-2 (MFN2), or mitochondrial dysfunction, are described. Methods of treatment and pharmaceutical formulations are also described.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: August 10, 2021
    Assignee: Mitochondria Emotion, Inc.
    Inventor: Gerald W. Dorn, II
  • Cancer treatment
    Patent number: 11077106
    Abstract: The present invention provides a method for the treatment of cancer with erdafitinib.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: August 3, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kim Stuyckens, Juan Jose Perez Ruixo, Peter Marie Z. De Porre, Anjali Narayan Avadhani, Yohann Loriot, Arlene O. Siefker-Radtke
  • Lipid formulations containing bioactive fatty acids
    Patent number: 11058656
    Abstract: Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions containing defined ratios of 5,11,14-eicosatrienoic acid to one or more of: 5,9,12-octadecatrienoic acid; 7,11,14-eicosatrienoic acid; 5,8,11,14-eicosatetraenoic acid; 9,12-octadecadienoic acid; 9-octadecenoic acid; 14-methyl hexadecanoic acid; 11,14 eicosadienoic acid, 5,9-octadecadienoic acid; 5,11-octadecadienoic acid; 9,12,15-octadecatrienoic acid; 5,8,11,14,17-eicosapentaenoic acid; 7,10,13,16,19-docosapentaenoic acid; and 4,7,10,13,16,19-docosahexaenoic acid.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: July 13, 2021
    Assignee: SCIADONICS, INC.
    Inventor: Alvin Berger
  • Methods of reducing RLP-C
    Patent number: 11052063
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: July 6, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Oral dosage form comprising rifaximin in form beta
    Patent number: 11052071
    Abstract: The present invention relates to an oral dosage form containing rifaximin in form beta, wherein the oral dosage form provides delayed release of the active pharmaceutical agent. Further, the invention relates to the preparation of an oral dosage form, preferably a tablet.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: July 6, 2021
    Assignee: Sandoz AG
    Inventor: Franz Xaver Schwarz
  • Sphingosine kinase 2 inhibitor for treating coronavirus infection
    Patent number: 11052073
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: July 6, 2021
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi
  • Cysteine composition and injection
    Patent number: 11045438
    Abstract: Cysteine compositions comprising less than about 400 ?g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 ?g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: June 29, 2021
    Assignee: Exela Sterile Medicines LLC
    Inventors: Angela Sutterer, Jill Simpson, Gauthier Pouliquen, Alain Constancis, Pierre Danner
  • Non-digestible sugar-coated products and process
    Patent number: 11033503
    Abstract: A method and composition are provided for coating a component to achieve colon-targeted delivery. A component is coated with a fructose-based non-digestible carbohydrate such as a inulin, fructo-oligosaccharide or neosugar. The coated component is orally administered to a monogastric animal. The non-digestible coating causes the composition to pass through the stomach and small intestine without being degraded, and delivers the component to the colon where the coating is digested by microbial fermentation and the component is released.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: June 15, 2021
    Inventor: Guy W Miller
  • Devices and methods for facilitating and controlling use of a medication
    Patent number: 11033530
    Abstract: A device includes a reservoir configured to store a drug formulation including at least one abuse-preventing additive. The device further includes means configured to remove the at least one abuse-preventing additive. The device further includes means configured to prevent access to the drug formulation.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: June 15, 2021
    Assignee: JAZZ PHARMACEUTICALS, INC.
    Inventor: Clark Allphin
  • Methods of providing weight loss therapy in patients with major depression
    Patent number: 11033543
    Abstract: Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: June 15, 2021
    Assignee: Nalpropion Pharmaceuticals LLC
    Inventors: Eduardo Dunayevich, Gary Tollefson
  • Selective estrogen receptor degrader
    Patent number: 11014915
    Abstract: A selective estrogen receptor degrader (SERD), a compound 3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, and its S enantiomer, (2S)-3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, or pharmaceutically acceptable salts thereof. Also provided are processes for their preparation. Also provided for is the use of these compounds for the treatment of diseases which are related to modulation of estrogen receptors, such as ER-positive breast cancer.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: May 25, 2021
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
    Inventors: Rajan Kumar Pal, Biswajit Samanta, Jayraj Dilipbhai Aradhye, Sandeep Pankajkumar Pathak, Kaushik Dhanjibhai Prajapati, Bhavesh Mohanbhai Panchal, Trinadha Rao Chitturi
  • Antifungal composition containing caryolan-1-ol
    Patent number: 11000032
    Abstract: The present invention relates to an antibacterial or plant disease control composition containing caryolan-1-ol. According to the present invention, the caryolan-1-ol, as a volatile substance isolated from a Streptomyces sp. strain, has an excellent antifungal effect on various plant pathogens including Botrytis cinerea, Fusarium oxysporum, Phytophthora nicotinae, Colletotrichum gloeosporioides, Rhizoctonia cerealis, Rhizoctonia solani and Gibberella moniliformis and the like, and has storage disease preventive and herbicidal activity, thereby being usable as an antibacterial composition and a plant disease control composition.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: May 11, 2021
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventors: Youn-Sig Kwak, Chung Gyoo Park, Gyeongjun Cho, Junheon Kim
  • Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea
    Patent number: 10993923
    Abstract: The present invention provides an application of 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea in preparation of drugs for treating and reducing a fibrotic disease. The fibrotic disease is skin sclerosis, cardiac fibrosis, pulmonary fibrosis, hepatic fibrosis, pancreatic fibrosis, or renal fibrosis.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: May 4, 2021
    Inventors: Kuen-Feng Chen, Chung-Wai Shiau
  • Sprayable aqueous composition comprising glyceryl trinitrate
    Patent number: 10987332
    Abstract: The present application relates to a pharmaceutical preparation comprising (a) from 0.15 to 3 weight percent of glyceryl trinitrate, (b) from 40 to 95 weight percent water, and (c1) from 2 to 10 weight percent of at least one water soluble polymer, or (c2) from 1 to 10 weight percent of at least one water soluble polymer and 5 to 20 weight percent of ethanol.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: April 27, 2021
    Assignee: G. POHL-BOSKAMP GMBH & CO. KG
    Inventors: Andreas Gerber, Michaela Gorath, Thomas Zimmeck
  • TFEB activator C1 ameliorates app and tau pathology and rescues cognitive deficits in neurodegenerative diseases
    Patent number: 10987319
    Abstract: The present invention relates to a method of use of a composition comprising an autophagy enhancement compound for treating neurodegenerative diseases. In particular, the said composition is used to treat the neural condition of synaptic dysfunction. Such neurodegenerative diseases include Parkinson's disease, Alzheimer's disease, Huntington's disease, Frontotemporal dementia with parkinsonism-17 (FTDP-17), Pick disease (PiD), Progressive supranuclear palsy (PSP), Corticobasal degeneration (CBD) and Cerebral amyloid angiopathy.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: April 27, 2021
    Assignee: Hong Kong Baptist University
    Inventors: Min Li, Juxian Song, Sandeep Malampati
  • Vitamin D composition
    Patent number: 10966992
    Abstract: The invention is directed to compositions of vitamin D having enhanced bioavailability and enhanced stability. Methods of making and using the compositions of the invention are contemplated and disclosed.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: April 6, 2021
    Inventors: Bruce L. Howe, Kodimule Shyam Prasad
  • Suppositories comprising cannabinoids
    Patent number: 10959978
    Abstract: This invention relates to a suppository composition comprising cannabinoids. The suppository composition is formulated for easy absorption through mucosal membrane. The suppository as provided herein is useful for administration of cannabinoids in patients with nausea, vomiting, other conditions preventing swallowing, or conditions wherein suppository administration is required. Methods to manufacture the suppository composition are provided. Methods to treat pain, nausea, post-operative ileus and/or inflammatory bowel diseases using the suppository according to this invention are also provided.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: March 30, 2021
    Assignee: APIRX Pharmaceutical USA, LLC
    Inventors: Lekhram Changoer, George Anastassov
  • Formulations with reduced degradation of polysorbate
    Patent number: 10933141
    Abstract: The invention provides methods for making such formulations and methods of using such formulations. The invention further provides methods of reducing polysorbate degradation, methods of reducing the amount of visible and sub-visible particles in an aqueous formulation, and methods of disaggregating polysorbate degradation products comprising adding a cyclodextrin to a formula comprising polysorbate and a polypeptide. The invention also provides aqueous formulations comprising a polypeptide, a polysorbate, and a cyclodextrin with reduced polysorbate degradation.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: March 2, 2021
    Assignee: GENENTECH, INC.
    Inventors: Brian Connolly, Lydia Hamburg, Emily Holz
  • No-donors for the treatment of cerebrovascular vasospasms after brain hemorrhage
    Patent number: 10918643
    Abstract: The present invention relates to the combined use of NO-donors for the treatment, prevention and/or amelioration of disturbances of the cerebral macro- and microcirculation which disturbances cause cerebrovascular spasms (CVS) and/or malperfusion of brain parenchyma caused by blood vessel and blood flow dysregulation.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: February 16, 2021
    Assignee: Westfaelische Wilhelms-Universitaet Muenster
    Inventor: Angelika Ehlert
  • Phospholipid preparations for the improvement of sleep
    Patent number: 10894056
    Abstract: Phospholipid preparations for the improvement of sleep and/or treatment of sleep disorders. Methods of improving sleep and/or treating sleep disorders comprising administering the same.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: January 19, 2021
    Assignee: ENZYMOTEC LTD
    Inventors: Gali Olga Soria Artzi, Yael Richter, Arnold W. Mech